Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): a randomized trial

Jeremić, Branislav; Shibamoto, Yuta; Miličić, Biljana; Milisavljević, Slobodan; Nikolic, Nebojsa; Dagović, Aleksandar; Aleksandrovic, Jasna; Radosavljevic-Asic, G.

doi:10.1016/s0169-5002(99)00061-6

Cited by 7 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the two studies have been published in detail [17,18]. The results of the two studies have been published in detail [17,18].…”

Section: Resultsmentioning

confidence: 99%

“…During a 7-year period (1988)(1989)(1990)(1991)(1992)(1993)(1994), two consecutive prospective randomised studies were performed at our institution [17,18]. To be eligible for these studies, adult patients had to have histologically or cytologically proven stage IV NSCLC according to the International System, Karnofsky performance status (KPS) =50, measurable or evaluable disease, normal haematological (WBC =4000/ll, platelets =100,000/ll, hemoglobin =10 g/dl), hepatic (serum bilirubin <1.5 mg/dl), and renal (serum creatinine <1.5 mg/dl) function, a life expectancy of at least 3 months, and no prior therapy.…”

Section: Methodsmentioning

confidence: 99%

“…In an attempt to contribute to the ongoing controversy, we therefore undertook an analysis of potential clinical pre-treatment prognostic factors in patients with metastatic (stage IV) NSCLC treated with CHT during two consecutive prospective randomised trials [17,18]. A number of pre-treatment clinical and biological factors have been studied over the years.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy

Jeremić

Miličić

Dagović

et al. 2003

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Purpose: We investigated the influence of potential pre-treatment clinical prognostic factors in stage IV non-small cell lung cancer (NSCLC). Methods and patients: A total of 285 patients were enrolled in two consecutive prospective randomised studies which compared (study 1) carboplatin and prolonged oral etoposide (group 1; n=58) with the same etoposide alone (group 2; n=59), and (study 2) carboplatin and prolonged oral etoposide (group 1; n=84) with the same carboplatin and high-dose intravenous etoposide (group 2; n=84). Results: The median survival time for all 285 patients was 7 months, while 1-and 2-year survival rates were 29% and 8%, respectively. Age did not impact on outcome (P=0.21), while female patients did significantly better than male patients (P<0.0001). Patients with KPS 80-100 did significantly better than those with KPS 50-70 (P<0.0001), as did patients with less pronounced weight loss (P<0.0001) and those with only one metastatic site when compared to those having at least two metastatic sites (P<0.0001). When evaluated regarding the metastatic site, only subcutaneous metastatic site did not influence survival. This was confirmed within univariate analyses, but when multivariate analyses were done gender, KPS, weight loss, number of metastatic sites, presence of liver metastases and presence of brain metastases independently influenced survival, while age and other metastatic locations did not. Conclusion: In this analysis, gender, KPS, weight loss, number of metastatic sites, presence of liver metastases and presence of brain metastases independently influ-enced survival in patients with stage IV NSCLC treated with CHT.

show abstract

“…The results of the two studies have been published in detail [17,18]. The results of the two studies have been published in detail [17,18].…”

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy

Jeremić

Miličić

Dagović

et al. 2003

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…is significantly better to that of IV etoposide. In this cohort, there was a significantly higher need for hospitalization due to neutropenia in the IV group compared to the oral group [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

et al. 2018

View full text Add to dashboard Cite

High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (≤ 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan–Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.

show abstract

“…This regimen can easily achieve the continuous treatment in outpatient setting due to its lower toxicity, and can keep the preferable quality of life of the patients without any adverse effect due to the chemotherapy. It is reported that high-dose intravenous chemotherapy is not necessarily superior to prolonged oral chemotherapy in lung and colon cancers [20,21].…”

mentioning

confidence: 99%

Survival benefits of adjuvant chemotherapy with oral doxifluridine (5′‐DFUR) following radiotherapy in patients with unresectable pancreatic cancer

Takada

Okamoto

Egawa

et al. 2001

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): a randomized trial

Cited by 7 publications

References 45 publications

Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy

Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Survival benefits of adjuvant chemotherapy with oral doxifluridine (5′‐DFUR) following radiotherapy in patients with unresectable pancreatic cancer

Contact Info

Product

Resources

About